Transcription factor ELK3 promotes stemness and oxaliplatin resistance of glioma cells by regulating RNASEH2A
Y Mei, D Chen, S He, J Ye, M Luo… - Hormone and …, 2023 - thieme-connect.com
Oxaliplatin is a member of the platinum group that is often used to treat glioma, a common
type of malignant brain tumor, though it does not come with desirable and notable effects …
type of malignant brain tumor, though it does not come with desirable and notable effects …
Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A
Y Mei, D Chen, S He, J Ye, M Luo… - Hormone and …, 2023 - pubmed.ncbi.nlm.nih.gov
Oxaliplatin is a member of the platinum group that is often used to treat glioma, a common
type of malignant brain tumor, though it does not come with desirable and notable effects …
type of malignant brain tumor, though it does not come with desirable and notable effects …
Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A.
Y Mei, D Chen, S He, J Ye, M Luo, Q Wu… - Hormone and …, 2023 - europepmc.org
Oxaliplatin is a member of the platinum group that is often used to treat glioma, a common
type of malignant brain tumor, though it does not come with desirable and notable effects …
type of malignant brain tumor, though it does not come with desirable and notable effects …
Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A
Y Mei, D Chen, S He, J Ye, M Luo… - Hormone and …, 2023 - thieme-connect.com
Oxaliplatin is a member of the platinum group that is often used to treat glioma, a common
type of malignant brain tumor, though it does not come with desirable and notable effects …
type of malignant brain tumor, though it does not come with desirable and notable effects …